CF PharmTech (02652) announced that its inhalation formulation production base in Suzhou has successfully passed an on-site Good Manufacturing Practice (GMP) inspection conducted by the drug regulatory authority of a member country of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). The review covered production management, quality control systems, premises, facilities, equipment, data integrity and computerized systems. Passing the audit confirms that the plant meets PIC/S GMP standards.
The clearance establishes a crucial market entry channel for CF PharmTech’s inhalation formulations in a jurisdiction with a population numbering in the hundreds of millions and a substantial prevalence of asthma and chronic obstructive pulmonary disease (COPD). Local access to inhalation therapies in that market remains below the international average, offering a tangible commercial opportunity once product registrations are completed.
The Suzhou site already holds China GMP certification and has previously passed European Union Qualified Person (QP) audits. The latest PIC/S endorsement provides additional validation of the Group’s global-standard manufacturing platform and aligns with its strategy to supply high-quality, cost-effective respiratory treatments to overseas markets.
Management emphasized that the inspection result relates solely to manufacturing quality systems. Actual product launch in the target market will still depend on meeting all local registration, import approval and commercial requirements, and is subject to prevailing market conditions. Shareholders and potential investors are advised to consider these factors when evaluating the company’s prospects.
Comments